Send the following on WhatsApp
Continue to ChatESMO 2020 肺癌亮點:osimertinib 降低腦轉移風險達 8 成、amivantamab 聯合 lazertinib ORR 達 100%? https://geneonline.news/esmo-2020-egfrm-nsclc-treatment/
ESMO 2020 肺癌亮點:osimertinib 降低腦轉移風險達 8 成、amivantamab 聯合 lazertinib ORR 達 100%? https://geneonline.news/esmo-2020-egfrm-nsclc-treatment/